Article

Foldable intraocular telescope holds promise for patients with end-stage AMD

With approximately 14 million Americans with end-stage age-related macular degeneration (AMD), the latest developments in low vision aids for these patients is welcoming, noted Gholam A. Peyman, MD.

With approximately 14 million Americans with end-stage age-related macular degeneration (AMD), the latest developments in low vision aids for these patients is welcoming, noted Gholam A. Peyman, MD.

Dr. Peyman, professor of ophthalmology, Tulane University School of Medicine, New Orleans, described the steps leading up to the development of the Foldable Intraocular Telescope (FIT). He spoke during the Innovator's Session at the American Society of Cataract and Refractive Surgery annual meeting.

In 1988, he presented the concept behind FIT, which is basically a posterior chamber IOL with a telescopic zone and peripheral zone.

"The patient will be able to have full peripheral visual field without spectacles," Dr. Peyman said. "If the patient would like to read, he uses the plus lens in the telescope and the minus lens inside the eye. It provides 2.4x magnification."

From this concept, the foldable version, FIT, was developed with bifocal capabilities. This 5.8-mm foldable IOL system consists of a telescope measuring 1.5 mm in diameter and 3.5 mm in height. A 4.5-mm corneal incision is need for its implantation, he said.

"FIT provides patients with 3x magnification. For the surgeon it provides easier implantation," he said.

Dr. Peyman also discussed the development of a power-adjustable contact lens for the correction of myopia, hyperopia, and astigmatism. One of the advantages of this lens is the ability to correct higher-order aberrations, Dr. Peyman said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.